{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T00:15:52Z","timestamp":1772928952798,"version":"3.50.1"},"reference-count":23,"publisher":"Japanese Society of Toxicology","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Toxicol. Sci."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2131\/jts.51.201","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T22:10:15Z","timestamp":1772316615000},"page":"201-213","source":"Crossref","is-referenced-by-count":0,"title":["Human erythropoietin mRNA as an impurity from a mRNA-LNP vaccine induces immune-mediated anemia in rats"],"prefix":"10.2131","volume":"51","author":[{"given":"Yukie","family":"Murata","sequence":"first","affiliation":[{"name":"Shionogi Pharmaceutical Research Center, Shionogi &amp; Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Kitamura","sequence":"additional","affiliation":[{"name":"Shionogi Pharmaceutical Research Center, Shionogi &amp; Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiji","family":"Asaoka","sequence":"additional","affiliation":[{"name":"Shionogi Pharmaceutical Research Center, Shionogi &amp; Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun","family":"Kitahata","sequence":"additional","affiliation":[{"name":"Shionogi Pharmaceutical Research Center, Shionogi &amp; Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisaku","family":"Wakabayashi","sequence":"additional","affiliation":[{"name":"Shionogi Pharmaceutical Research Center, Shionogi &amp; Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetoshi","family":"Kouno","sequence":"additional","affiliation":[{"name":"Shionogi Pharmaceutical Research Center, Shionogi &amp; Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norikazu","family":"Kuroda","sequence":"additional","affiliation":[{"name":"Shionogi Pharmaceutical Research Center, Shionogi &amp; Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayo","family":"Ishida","sequence":"additional","affiliation":[{"name":"Shionogi Pharmaceutical Research Center, Shionogi &amp; Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinobu","family":"Miki","sequence":"additional","affiliation":[{"name":"Shionogi Pharmaceutical Research Center, Shionogi &amp; Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Sato","sequence":"additional","affiliation":[{"name":"Shionogi Pharmaceutical Research Center, Shionogi &amp; Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Shionogi Pharmaceutical Research Center, Shionogi &amp; Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Kugimiya","sequence":"additional","affiliation":[{"name":"Shionogi Pharmaceutical Research Center, Shionogi &amp; Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomokazu","family":"Yoshinaga","sequence":"additional","affiliation":[{"name":"Shionogi Pharmaceutical Research Center, Shionogi &amp; Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamio","family":"Fukushima","sequence":"additional","affiliation":[{"name":"Shionogi Pharmaceutical Research Center, Shionogi &amp; Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"898","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Al-Humadi, N. (2017): Pre-clinical toxicology considerations for vaccine development. Vaccine, <b>35<\/b>, 5762-5767.","DOI":"10.1016\/j.vaccine.2017.09.021"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Bitounis, D., Jacquinet, E., Rogers, M.A. and Amiji, M.M. (2024): Strategies to reduce the risks of mRNA drug and vaccine toxicity. Nat. Rev. Drug Discov., <b>23<\/b>, 281-300.","DOI":"10.1038\/s41573-023-00859-3"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Casadevall, N., Nataf, J., Viron, B., Kolta, A., Kiladjian, J.J., Martin-Dupont, P., Michaud, P., Papo, T., Ugo, V., Teyssandier, I., Varet, B. and Mayeux, P. (2002): Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med., <b>346<\/b>, 469-475.","DOI":"10.1056\/NEJMoa011931"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Chaudhary, N., Weissman, D. and Whitehead, K.A. (2021): mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat. Rev. Drug Discov., <b>20<\/b>, 817-838.","DOI":"10.1038\/s41573-021-00283-5"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Chenuaud, P., Larcher, T., Rabinowitz, J.E., Provost, N., Cherel, Y., Casadevall, N., Samulski, R.J. and Moullier, P. (2004): Autoimmune anemia in macaques following erythropoietin gene therapy. Blood, <b>103<\/b>, 3303-3304.","DOI":"10.1182\/blood-2003-11-3845"},{"key":"6","unstructured":"ICH. (2006): Impurities in new drug substances. https:\/\/www.pmda.go.jp\/files\/000156346.pdf"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Jelkmann, W. (1992): Erythropoietin: structure, control of production, and function. Physiol. Rev., <b>72<\/b>, 449-489.","DOI":"10.1152\/physrev.1992.72.2.449"},{"key":"8","unstructured":"Kaushansky, K., Lichtman, M.A., Beutler, E., Kipps, T.J., Seligsohn, U. and Prchhal, J.T. (2010): Williams Hematology."},{"key":"9","doi-asserted-by":"crossref","unstructured":"Khan, S., von Itzstein, M.S., Lu, R., Bermas, B.L., Karp, D.R., Khan, S.A., Fattah, F.J., Park, J.Y., Saltarski, J.M., Gloria-McCutchen, Y., Xie, Y., Li, Q.Z., Wakeland, E.K. and Gerber, D.E. (2020): Late-onset immunotherapy toxicity and delayed autoantibody changes: checkpoint inhibitor-induced Raynaud\u2019s-like phenomenon. Oncologist, <b>25<\/b>, e753-e757.","DOI":"10.1634\/theoncologist.2019-0666"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Lelis, F., Byk, L.A., Pustylnikov, S., Nguyen, V., Nguyen, B., Nitz, M., Tarte, P., Tungare, K., Li, J., Manna, S., Maiti, S., Mehta, D.H., Sekar, N., Posadas, D.M., Dhamankar, H., Hughes, J.A., Aulisa, L., Khan, A., Melo, M.B. and Dey, A.K. (2023): Safety, immunogenicity and efficacy of an mRNA-based COVID-19 vaccine, GLB-COV2-043, in preclinical animal models. Sci. Rep., <b>13<\/b>, 21172.","DOI":"10.1038\/s41598-023-46233-6"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Liu, J., Chen, X., Chen, C., Wu, J., Xie, F., Li, J., Han, H., Zhao, Y. and Yang, Y. (2025): Nonclinical safety and biodistribution evaluation of HC009 mRNA vaccine against COVID-19 in rat. Toxicology, <b>514<\/b>, 154107.","DOI":"10.1016\/j.tox.2025.154107"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Lin, M., Yin, Y., Zhao, X., Wang, C., Zhu, X., Zhan, L., Chen, L., Wang, S., Lin, X., Zhang, J., Xia, N. and Zheng, Z. (2025): A truncated pre-F protein mRNA vaccine elicits an enhanced immune response and protection against respiratory syncytial virus. Nat. Commun., <b>16<\/b>, 1386.","DOI":"10.1038\/s41467-025-56302-1"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Renard, D. and Rosselet, A. (2017): Drug-induced hemolytic anemia: pharmacological aspects. Transfus. Clin. Biol., <b>24<\/b>, 110-114.","DOI":"10.1016\/j.tracli.2017.05.013"},{"key":"14","unstructured":"Ridley, D.M., Dawkins, F. and Perlin, E. (1994): Erythropoietin: a review. J. Natl. Med. Assoc., <b>86<\/b>, 129-135."},{"key":"15","doi-asserted-by":"crossref","unstructured":"Rohde, C.M., Lindemann, C., Giovanelli, M., Sellers, R.S., Diekmann, J., Choudhary, S., Ramaiah, L., Vogel, A.B., Chervona, Y., Muik, A. and Sahin, U. (2023): Toxicological assessments of a pandemic COVID-19 vaccine-demonstrating the suitability of a platform approach for mRNA vaccines. Vaccines (Basel), <b>11<\/b>, 417.","DOI":"10.3390\/vaccines11020417"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Sedic, M., Senn, J.J., Lynn, A., Laska, M., Smith, M., Platz, S.J., Bolen, J., Hoge, S., Bulychev, A., Jacquinet, E., Bartlett, V. and Smith, P.F. (2018): Safety evaluation of lipid nanoparticle-formulated modified mRNA in the sprague-dawley rat and cynomolgus monkey. Vet. Pathol., <b>55<\/b>, 341-354.","DOI":"10.1177\/0300985817738095"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Sellers, R.S., Nelson, K., Bennet, B., Wolf, J., Tripathi, N., Chamanza, R., Perron Lepage, M.F., Adkins, K., Laurent, S. and Troth, S.P. (2020): Scientific and regulatory policy committee points to consider*: approaches to the conduct and interpretation of vaccine safety studies for clinical and anatomic pathologists. Toxicol. Pathol., <b>48<\/b>, 257-276.","DOI":"10.1177\/0192623319875085"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Stone, C.A. Jr., Rukasin, C.R., Beachkofsky, T.M. and Phillips, E.J. (2019): Immune-mediated adverse reactions to vaccines. Br. J. Clin. Pharmacol., <b>85<\/b>, 2694-2706.","DOI":"10.1111\/bcp.14112"},{"key":"19","unstructured":"USP. (2022): Analytical procedures for mRNA vaccine quality (draft guidelines). https:\/\/www.uspnf.com\/notices\/analytical-procedures-mrna-vaccines-20220210"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Vanderlaan, M., Zhu-Shimoni, J., Lin, S., Gunawan, F., Waerner, T. and Van Cott, K.E. (2018): Experience with host cell protein impurities in biopharmaceuticals. Biotechnol. Prog., <b>34<\/b>, 828-837.","DOI":"10.1002\/btpr.2640"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Watanabe, K., Watanabe, R., Shioda, A., Mizoguchi, K., Sugimoto, T. and Terao, K. (2003): Investigation of the mechanism of drug-induced autoimmune hemolytic anemia in cynomolgus monkeys elicited by a repeated-dose of a humanized monoclonal antibody drug. J. Toxicol. Sci., <b>28<\/b>, 123-138.","DOI":"10.2131\/jts.28.123"},{"key":"22","unstructured":"WHO. (2005): WHO guidelines on nonclinical evaluation of vaccines. https:\/\/cdn.who.int\/media\/docs\/default-source\/biologicals\/annex1nonclinical.p31-63.pdf?sfvrsn=d11d7789_3&amp;download=true"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Wolff, J.A., Malone, R.W., Williams, P., Chong, W., Acsadi, G., Jani, A. and Felgner, P.L. (1990): Direct gene transfer into mouse muscle <i>in vivo.<\/i> Science, <b>247<\/b>, 1465-1468.","DOI":"10.1126\/science.1690918"}],"container-title":["The Journal of Toxicological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jts\/51\/3\/51_201\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T04:48:10Z","timestamp":1772858890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jts\/51\/3\/51_201\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2131\/jts.51.201","relation":{},"ISSN":["0388-1350","1880-3989"],"issn-type":[{"value":"0388-1350","type":"print"},{"value":"1880-3989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]}}}